Product Information
DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.9375 per EA under NDC 43598045360. Its NADAC has been published 81 times since Mar 19, 2025.
FDA first approved this application on Jan 28, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
110 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
43598045360
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208048FDA Approved
1/28/2025
TE Code
AB
On Market Since
2/28/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 81 times since Mar 19, 2025, and over the history we have for it it has declined 52.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9375 per EA |
|---|---|
| All-time high | $1.9786 (Apr 16, 2025) |
| All-time low | $0.9196 (May 20, 2026) |
| 52-week high | $1.8269 |
| 52-week low | $0.9196 |
| Median price | $1.4058 |
| Average price | $1.4350 |
| Largest weekly change | -12.4% (Dec 17, 2025) |
| Weeks tracked | 81 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dabigatran etexilate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dabigatran etexilate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Direct Thrombin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Dr. Reddy's Laboratories Inc., is $0.9375 per EA (NDC 43598045360), effective Sep 30, 2026.
How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 52.6%. It has been tracked across 81 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?
Since Mar 19, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.9786 (Apr 16, 2025), with a median of $1.4058 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?
No other NADAC-published product currently shares the active ingredient and strength of DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DABIGATRAN ETEXILATE 110 MG CP?
DABIGATRAN ETEXILATE 110 MG CP (NDC 43598045360) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.